Nutritional Management of Patients with Fatty Acid Oxidation Disorders

Author:

Peña-Quintana Luis12ORCID,Correcher-Medina Patricia23

Affiliation:

1. Pediatric Gastroenterology and Nutrition Unit, Insular Materno-Infantil University Hospital Complex, Asociación Canaria de Investigación Pediátrica, Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición ISCIII, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain

2. Asociación Española para el Estudio de los Errores Congénitos del Metabolismo (AECOM), 28221 Majadahonda, Spain

3. Metabolic and Nutrition Unit, Hospital Universitari i Politècnic la Fe, 46026 Valencia, Spain

Abstract

Treatment of fatty acid oxidation disorders is based on dietary, pharmacological and metabolic decompensation measures. It is essential to provide the patient with sufficient glucose to prevent lipolysis and to avoid the use of fatty acids as fuel as far as possible. Dietary management consists of preventing periods of fasting and restricting fat intake by increasing carbohydrate intake, while maintaining an adequate and uninterrupted caloric intake. In long-chain deficits, long-chain triglyceride restriction should be 10% of total energy, with linoleic acid and linolenic acid intake of 3–4% and 0.5–1% (5/1–10/1 ratio), with medium-chain triglyceride supplementation at 10–25% of total energy (total MCT+LCT ratio = 20–35%). Trihepatnoin is a new therapeutic option with a good safety and efficacy profile. Patients at risk of rhabdomyolysis should ingest MCT or carbohydrates or a combination of both 20 min before exercise. In medium- and short-chain deficits, dietary modifications are not advised (except during exacerbations), with MCT contraindicated and slow sugars recommended 20 min before any significant physical exertion. Parents should be alerted to the need to increase the amount and frequency of carbohydrate intake in stressful situations. The main measure in emergency hospital treatment is the administration of IV glucose. The use of carnitine remains controversial and new therapeutic options are under investigation.

Funder

Spanish Society for the Study of Inborn Errors of Metabolism

Publisher

MDPI AG

Reference37 articles.

1. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle;Knottnerus;Rev. Endocr. Metab. Disord.,2018

2. Newborn cribado for disorders of fatty-acid oxidation: Experience and recomendations from an expert meeting;Lindner;J. Inherit. Metab. Dis.,2010

3. Expanded newborn screening: Outcome in screened and unscreened patients at age 6 years;Wilcken;Pediatrics,2009

4. Couce, M.L., Aldámiz-Echevarría, L., Jiménez, C.G., and Lamuño, D.G. (2022). Alteraciones de la β-oxidación de los ácidos grasos y del sistema carnitina. Diagnóstico y Tratamiento de las Enfermedades Metabólicas Hereditarias, Ergón. [5th ed.].

5. Disorders of Carnitine Transport and the Carnitine Cycle;Longo;Am. J. Med. Genet. Part C Semin. Med. Genet.,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3